VSTM Company Profile and Key Details

Q: Who are the executives of VSTM?

Mr. Sean C. FlynnSenior Vice President, Gen. Counsel & Sec.Mr. Richard H. Aldrich M.B.A., MbaFounder and ConsultantDr. Robert A. Weinberg Ph.D.Co-Founder & Chair of Scientific Advisory BoardMr. Daniel CalkinsHead of Investor Relations, Vice President of Fin. and Principal Accounting Officer & Financial OfficerDr. Piyush B. Gupta Ph.D.Co-FounderMs. Erin S. CoxSenior Director of Investor Relations & Corporation CommunicationsDr. Michelle Dipp M.D., Ph.D.Co-FounderMr. Daniel W. PatersonPres, Chief Executive Officer & DirectorMs. Lisa BuffingtonSenior Vice President of Corporation Communications & Patient AdvocacyMr. Brian M. Stuglik BPHARM, R.Ph., RPhChief Executive Officer & DirectorLisa BuffingtonHead of Corporation CommunicationsMr. Ajay MunshiVice President of Corporation Devel.Mr. Brian M. Stuglik BPHARM, RPhChief Executive Officer & DirectorDr. Jonathan Pachter Ph.D.Chief Scientific Officer

NASDAQ : VSTM

Verastem

$6.35

-0.3013-4.53%

Open: 3:28 PM

70.95

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Verastem, Inc. (VSTM) stock declined over -4.53%, trading at $6.35 on NASDAQ, down from the previous close of $6.65. The stock opened at $6.53, fluctuating between $6.31 and $6.77 in the recent session.

Stock Snapshot

6.65

Prev. Close

384.34M

Market Cap

6.31

Day Low

-1.48

P/E Ratio

-4.28

EPS (TTM)

-3.23

Cash Flow per Share

6.53

Open

60.54M

Number of Shares

6.7701

Day High

92.76%

Free Float in %

2.93

Book Value

846.43K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 20, 2026	6.60	6.95	6.45	6.65	1.51M
Jan 16, 2026	7.12	7.12	6.50	6.68	2.03M
Jan 15, 2026	6.81	7.03	6.56	6.60	2.39M
Jan 14, 2026	7.16	7.26	6.74	6.79	1.97M
Jan 13, 2026	7.12	7.25	6.91	7.20	1.09M
Jan 12, 2026	7.74	7.74	7.01	7.11	2.44M
Jan 09, 2026	8.12	8.35	7.74	7.79	2.17M
Jan 08, 2026	7.50	8.13	7.49	7.87	3.05M
Jan 07, 2026	6.92	8.88	6.90	7.64	6.88M
Jan 06, 2026	6.83	7.07	6.74	6.88	1.19M
Jan 05, 2026	7.29	7.37	6.68	6.87	1.95M
Jan 02, 2026	7.74	7.76	7.19	7.23	1.25M
Dec 31, 2025	7.54	7.77	7.47	7.72	989.99K
Dec 30, 2025	7.67	7.79	7.47	7.54	1.31M
Dec 29, 2025	7.97	8.03	7.68	7.76	994.48K
Dec 26, 2025	7.80	8.14	7.71	8.06	891.69K
Dec 24, 2025	7.86	8.08	7.77	7.87	734.78K
Dec 23, 2025	7.85	7.99	7.77	7.93	1.09M
Dec 22, 2025	7.72	8.23	7.70	7.90	1.64M
Dec 19, 2025	7.76	8.07	7.59	7.76	5.31M

Contact Details

Needham, MA 02494

United States

https://www.verastem.com 781 292 4200

About Company

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Stock Peers

ARGX

9.63+1.20%

argenx SE$809.64 REGN

0.74+0.10%

Regeneron Pharmaceuticals, Inc.$733.78 MDGL

3.27+0.65%

Madrigal Pharmaceuticals, Inc.$504.95 UTHR

3.14+0.68%

United Therapeutics Corporation$468.07 VRTX

0.72+0.16%

Vertex Pharmaceuticals Incorporated$442.08 ALNY

-3.74-1.04%

Alnylam Pharmaceuticals, Inc.$355.53 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

6.83+2.15%

Praxis Precision Medicines, Inc.$324.08 KRYS

-10.23-3.59%

Krystal Biotech, Inc.$274.81 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Verastem, Inc. (NASDAQ:VSTM) closed at $6.35 USD, losing -$0.30 (-4.53%) from the previous close of $6.65. The stock is currently mid-range between its 52-week high and low $4.01 and $11.25. With a market capitalization of about $384.34 million, Verastem, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.44). Key stats such as the average daily volume over the past year has been around 2.25 million shares, volume is running light vs its 52-week average. Headquartered in Needham, MA, Verastem, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daniel W. Paterson, the company employs approximately 78 people and listed since January 27, 2012. Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer.

Technical Performance

VSTM has shown weak momentum, losing -6.47% over the past week and -27.87% over the past quarter, though year-to-date performance is down -13.86%. Short-term trend indicators are mixed aligned (SMA20 -10.04%, SMA50 -22.27%, SMA200 -11.85%). The stock’s 14-day RSI is 34.52 (weak momentum), while the ATR of 0.59 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -40.86% below its high and over 65.84% above its low. Average 10-day trading volume of 1.91 million shares is below the 3-month average of 2.18 million, indicating normal recent market interest.

Valuation Metrics

Verastem, Inc. trades at a P/E ratio of -2.03, slightly below the S&P 500 average, with a price-to-sales ratio of 30.29 and a price-to-book ratio of -31.55 indicating negative book value, which may reflect financial stress. The P/FCF stands at -3.06, also below market averages.

Dividend & Fair Value

Verastem, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.02. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Verastem, Inc. generated EPS of -$4.26 over the past year. Five-year average earnings growth is 31.36%. Wall Street analysts project EPS growth of 37.85% annually over the next five years. The latest quarter delivered EPS of -$1.35. The next quarter is forecast at -$0.52. Next year's EPS is expected at $6.44. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $8.00. The high target offers 200.75% upside. The low target suggests 20.3% downside. The mean target is $12.78. This offers 92.18% upside. Verastem, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 164.05%. The prior quarter beat by -54.12%. Over the last six quarters, Apple has recorded several small beats. These include -70.75% in August 08, 2024.

Shareholding & Insider Activity

Verastem, Inc. has 61.55 million shares outstanding. The public float is 45.88 million shares, elevated short interest at 26.04% of float. This equals 15.96 million shares. The short ratio is 5.46 days. Institutional investors hold 87.18% of the float. Insiders own 0.59%. RA CAPITAL MANAGEMENT, L.P. holds 16.14 million shares, Paterson Dan has 400.10 thousand shares and Forrester Robert has 221.23 thousand shares. Over the past six months, insider transactions show net selling. They sold 72.51 thousand shares across 30 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Verastem has not generated any revenue. Returns are negative, with ROA at -58.35% and ROE at -111.25%.
On valuation metrics, Verastem trades at a P/E of -2.03, P/S of 30.29 and P/B of -31.55. The current ratio is 2.58 and quick ratio is 2.55. Operationally, the company’s inventory turnover is 1.18 and cash conversion cycle is -1212.95 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -5.76, supported by a cash flow-to-debt ratio of -1.48.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Verastem posted revenue of $0.00, down slightly from $2.60M in the prior quarter. Gross profit was - $62.00K (margin 0.00%). Operating income was - $92.08M (margin 0.0%). Net income was- $87.37M (EPS - $3.96).
The company ended the quarter with $138.06M in cash and short-term investments, a total debt of $41.56M, and net debt of - $37.28M. Total assets were $149.72M, with equity of $78.53M. Financials further reflected weakness, with operating cash flow of - $86.46M, free cash flow of - $86.45M, and capital expenditures of $7.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Verastem, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.98%, with price expected at $5.72 by February 03, 2026, within a range of $5.28 to $6.21 3-Month Outlook: Projected fall of -32.78%, reaching $4.47 by April 16, 2026, with a range of $4.27 to $4.68. 1-Year Outlook: Projected gain of 131.28%, with price at $15.38 by January 15, 2027, within a range of $3.58 to $26.36.

Key Takeaways

Verastem, Inc. (NASDAQ:VSTM) shares are down -13.86% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Verastem, Inc. trading at a premium to the broader market with a P/E of -2.03. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.19, suggesting 128.42% upside. Our AI forecast model points to short-term weakness (-13.98% over two weeks), a medium-term fall (-32.78% over three months), and a longer-term gain (131.28% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Verastem, Inc. (VSTM) stock price?

Verastem, Inc. (NASDAQ: VSTM) stock price is $6.35 in the last trading session. During the trading session, VSTM stock reached the peak price of $6.77 while $6.31 was the lowest point it dropped to. The percentage change in VSTM stock occurred in the recent session was -4.53% while the dollar amount for the price change in VSTM stock was - $0.30.

VSTM's industry and sector of operation?

The NASDAQ listed VSTM is part of Biotechnology industry that operates in the broader Healthcare sector. Verastem, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of VSTM?

Mr. Sean C. Flynn
Senior Vice President, Gen. Counsel & Sec.
Mr. Richard H. Aldrich M.B.A., Mba
Founder and Consultant
Dr. Robert A. Weinberg Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Mr. Daniel Calkins
Head of Investor Relations, Vice President of Fin. and Principal Accounting Officer & Financial Officer
Dr. Piyush B. Gupta Ph.D.
Co-Founder
Ms. Erin S. Cox
Senior Director of Investor Relations & Corporation Communications
Dr. Michelle Dipp M.D., Ph.D.
Co-Founder
Mr. Daniel W. Paterson
Pres, Chief Executive Officer & Director
Ms. Lisa Buffington
Senior Vice President of Corporation Communications & Patient Advocacy
Mr. Brian M. Stuglik BPHARM, R.Ph., RPh
Chief Executive Officer & Director
Lisa Buffington
Head of Corporation Communications
Mr. Ajay Munshi
Vice President of Corporation Devel.
Mr. Brian M. Stuglik BPHARM, RPh
Chief Executive Officer & Director
Dr. Jonathan Pachter Ph.D.
Chief Scientific Officer

How VSTM did perform over past 52-week?

VSTM's closing price is 65.83% higher than its 52-week low of $4.01 where as its distance from 52-week high of $11.25 is -40.89%.

How many employees does VSTM have?

Number of VSTM employees currently stands at 78.

Link for VSTM official website?

Official Website of VSTM is: https://www.verastem.com

How do I contact VSTM?

VSTM could be contacted at phone 781 292 4200 and can also be accessed through its website. VSTM operates from 117 Kendrick Street, Needham, MA 02494, United States.

How many shares of VSTM are traded daily?

VSTM stock volume for the day was 846.43K shares. The average number of VSTM shares traded daily for last 3 months was 2.25M.

What is the market cap of VSTM currently?

The market value of VSTM currently stands at $384.34M with its latest stock price at $6.35 and 60.54M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	78
Beta	0.44
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

VSTM Company Profile and Key Details

Verastem

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways